Johnson & Johnson says a booster dose of its COVID-19 vaccine prompts a large increase in immune response.
The company reports that people who received a booster shot six to eight months after the initial shot saw antibodies increase nine-fold.
Phase 2 studies have been underway in the United States and Europe, as the world looks ahead to full FDA approval of the shot, as well as federal approval of booster shots heading into the fall.
“We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,” Dr. Mathai Mammen, of Janssen said in a statement.
“We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination,” Mammen continued.
For weeks, as talks and approvals of booster shots in the U.S. for those that received the Moderna and Pfizer vaccines – J&J recipients have wondered when they would see similar information.
The J&J shot was initially viewed as a strong contender for mass vaccination because of its single-dose status.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected]